Kerala takes utmost care against spread of Nipah virus

News Network
June 3, 2019

Kochi, Jun 3: The Kerala government on Monday said a college student here is suspected to have been infected with the Nipah virus but a final confirmation is awaited from the National Institute of Virology in Pune.

The Kerala Health Department has initiated precautionary measures to deal with the possible outbreak of Nipah virus.

State Health Minister K K Shailaja said in Thiruvananthapuram that the 23-year-old college student, who has been admitted to a private hospital here, is suspected to have been infected with the Nipah virus but a final confirmation is awaited from the National Institute of Virology in Pune. She said isolation wards have been set up at the Kalamassery Medical College Hospital in Kochi.

Although the state government is awaiting a report from the Pune Virology Institute to confirm if the student has contracted the Nipah virus, the Health department in the state has geared up to deal with a possible outbreak, officials said here.

A meeting of officials of the Health Department and Ernakulam district authorities held here reviewed the situation. It was chaired by Principal Secretary (Health), Rajan Khobragade. A team of medical experts, who have experience in dealing with the situation, have been rushed to Ernakulam from Kozhikode, officials said after the meeting.

 A senior district health official said "good news" is being received from doctors attending on the student at the hospital.He had taken food in the morning and is responding to medicines, the official said.

Ernakulam district Collector Mohammed Y Saffirulla said steps have been taken for capacity building at government and private hospitals to deal with the situation. Surveillance teams have been constituted to follow the suspected cases of Nipah.

A facility to quarantine patients with suspected case of Nipah has been arranged at the Government Medical College, Kalamassery, he said. A control room would be opened at the district headquarters apart from a media cell to provide information to the media, he added.

Assuming that the student has contracted the Nipah virus, Health authorities have directed the people with whom the student had contacted to report to the nearest medical facility if they develop influenza-like symptoms like fever, headache, myalgia (muscle pain), vomiting and sore throat.

Health authorities in Thrissur said the student who was suffering from fever had sought medical assistance at two private hospitals in Thrissur city when he had come here for a training programme recently as part of his course. He is studying in Thodupuzha in Idukki district.

Thrissur District Medical Officer, Dr Reena, said six persons, who had been in direct contact with the student, were currently under observation. Besides, the people who contacted the student were also under watch, the DMO said. She said the student was in Thrissur only for four days and had been suffering from fever.

There were 16 other students with him and six of them, who came in direct contact with him, were under observation, she added. Idukki district medical authorities said the college in Thodupuzha, where the student is studying, is also under observation.

Officials said the family and neighbours of the young man, who hails from Ernakulam district were also under observation as was the college in Thodupuzha, where the student is studying.

The Health minister said there was no need for people to panic as the government has taken all precautionary measures and asked all private hospitals to inform them if suspected cases were reported.

On May 19, 2018, Nipah virus disease (NiV) outbreak was reported from Kozhikode in Malappuram district. As per state government figures, the Nipah virus had claimed 17 lives -- 14 in Kozhikode and three in neighbouring Malappuram in May last year.

According to the WHO, Nipah virus is a newly emerging disease that can be transmitted from its reservoir (natural wildlife host), the flying foxes (fruit bats), to both animals and humans. It takes its name from Sungai Nipah, a village in Malaysia where it was first identified.

Human infections can range from asymptomatic infection, acute respiratory infection (mild, severe), and fatal encephalitis. Infected people initially develop influenza-like symptoms of fever, headache, myalgia, vomiting and sore throat.

This can be followed by dizziness, drowsiness, altered consciousness, and neurological signs that indicate acute encephalitis. Some people can also experience atypical pneumonia and severe respiratory problems, including acute respiratory distress.

Encephalitis and seizures occur in severe cases, progressing to coma within 24 to 48 hours. The WHO said, "In the outbreak in Kerala, we are seeing patients with encephalitis, myocarditis and acute respiratory infection."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 24,2020

Thiruvananthapuram, May 24: Keralites on Sunday celebrated a low-key Eid-ul-Fitr amid the coronavirus lockdown in the state as most of the faithful marked the culmination of the fasting month of Ramzan by offering thanksgiving prayers at home.

The festival is being celebrated across Kerala and Jammu and Kashmir on Sunday, while the rest of the country will celebrate Eid on Monday.

Kerala Chief Minister Pinarayi Vijayan extended Eid-ul-Fitr greetings to all Keralites across the world.

State Governor Arif Mohammed Khan also extended his festival wishes to all the Keralites.

"May we also have the blessing to prevent and eliminate the COVID-19 disease," Khan tweeted.

Vijayan said this year Ramzan is celebrated at a time when the world is going through "an unprecedented crisis and misery" because of pandemic COVID-19.

"Usual celebration during Ramzan is not there anywhere in the world due to the pandemic. Instead of offering prayers at mosques, which is important for Muslims, this time the prayers and the feast is performed in their homes.

Community leaders have taken this important decision to protect the interests of the society" he added.

The chief minister said Eid-ul-Fitr gives out a message of equality, tolerance and repentance.

The state government had earlier announced that the lockdown restrictions in the state onSunday will be relaxed in the view of Eid-ul-Fitr with shops selling essential items remaining open.

The State government had earlier declared that a complete shutdown would be observed in Kerala on Sundays in order to contain the spread of the deadly virus.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.